Mr. Yusheng Han, Founder and CEO of Burning Rock stated: "We are thrilled to have carried out a deep companion diagnostic collaboration with the global biopharmaceutical company Dizal. This ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

Gene Park is a reporter for The Washington Post, covering video games and gaming culture. He joined The Post in 2015 as audience editor, and is a former reporter in the West Coast and Pacific region.

Background: Inhibitors of the anaplastic lymphoma kinase (ALK) gene mutation are first-line treatments in patients with ALK-positive lung cancer. The FDA label warns of the risk of interstitial lung ...

Researchers hope DeepGEM can expedite targeted treatment for lung cancer patients who can't access standard genomic testing.

Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy vector for hemophilia ... aspartate aminotransferase, or alkaline phosphatase that was more than twice the upper limit ...

ALK aims to avoid past merger mistakes by leveraging Hawaiian's assets and expanding its international presence, particularly in Asia and the South Pacific. The merger positions Alaska as a strong ...

Alaska Air Group (NYSE:ALK) announced it has completed its acquisition of Hawaiian Holdings (NASDAQ:HA). The airlines said they will now begin the work to secure a single operating certificate ...

Alkeus Pharmaceuticals Inc. announced that the SAGA study of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) ...

The most recent trading session ended with Alaska Air Group (ALK) standing at $40.98, reflecting a -0.87% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain ...

The candidate in question is gildeuretinol acetate, also called ALK-001, a form of deuterated vitamin A assessed in a phase 3 trial dubbed SAGA. The 24-month study enrolled 198 patients with GA ...